

AMENDMENTS TO LB 799

Introduced by Schilz

1           1. Insert the following new sections:

2           Sec. 2. Section 28-405, Revised Statutes Supplement,  
3 2011, is amended to read:

4           28-405 The following are the schedules of controlled  
5 substances referred to in the Uniform Controlled Substances Act:

6           Schedule I

7           (a) Any of the following opiates, including their  
8 isomers, esters, ethers, salts, and salts of isomers, esters, and  
9 ethers, unless specifically excepted, whenever the existence of  
10 such isomers, esters, ethers, and salts is possible within the  
11 specific chemical designation:

12           (1) Acetylmethadol;

13           (2) Allylprodine;

14           (3) Alphacetylmethadol, except levo-alphacetylmethadol  
15 which is also known as levo-alpha-acetylmethadol, levomethadyl  
16 acetate, and LAAM;

17           (4) Alphameprodine;

18           (5) Alphamethadol;

19           (6) Benzethidine;

20           (7) Betacetylmethadol;

21           (8) Betameprodine;

22           (9) Betamethadol;

23           (10) Betaprodine;

- 1 (11) Clonitazene;
- 2 (12) Dextromoramide;
- 3 (13) Difenoquin;
- 4 (14) Diampromide;
- 5 (15) Diethylthiambutene;
- 6 (16) Dimenoxadol;
- 7 (17) Dimepheptanol;
- 8 (18) Dimethylthiambutene;
- 9 (19) Dioxaphetyl butyrate;
- 10 (20) Dipipanone;
- 11 (21) Ethylmethylthiambutene;
- 12 (22) Etonitazene;
- 13 (23) Etozeridine;
- 14 (24) Furethidine;
- 15 (25) Hydroxypethidine;
- 16 (26) Ketobemidone;
- 17 (27) Levomoramide;
- 18 (28) Levophenacymorphan;
- 19 (29) Morpheridine;
- 20 (30) Noracymethadol;
- 21 (31) Norlevorphanol;
- 22 (32) Normethadone;
- 23 (33) Norpipanone;
- 24 (34) Phenadoxone;
- 25 (35) Phenampromide;
- 26 (36) Phenomorphan;
- 27 (37) Phenoperidine;

- 1 (38) Piritramide;
- 2 (39) Proheptazine;
- 3 (40) Properidine;
- 4 (41) Propiram;
- 5 (42) Racemoramide;
- 6 (43) Trimeperidine;
- 7 (44) Alpha-methylfentanyl,
- 8 N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl) propionanilide,
- 9 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
- 10 (45) Tilidine;
- 11 (46) 3-Methylfentanyl,
- 12 N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its
- 13 optical and geometric isomers, salts, and salts of isomers;
- 14 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its
- 15 optical isomers, salts, and salts of isomers;
- 16 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine,
- 17 its optical isomers, salts, and salts of isomers;
- 18 (49) Acetyl-alpha-methylfentanyl,
- 19 N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide, its
- 20 optical isomers, salts, and salts of isomers;
- 21 (50) Alpha-methylthiofentanyl,
- 22 N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,
- 23 its optical isomers, salts, and salts of isomers;
- 24 (51) Benzylfentanyl,
- 25 N-(1-benzyl-4-piperidyl)-N-phenylpropanamide, its optical
- 26 isomers, salts, and salts of isomers;
- 27 (52) Beta-hydroxyfentanyl,

1 N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide,  
2 its optical isomers, salts, and salts of isomers;  
3 (53) Beta-hydroxy-3-methylfentanyl, (other name:  
4 N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide),  
5 its optical and geometric isomers, salts, and salts of isomers;  
6 (54) 3-methylthiofentanyl,  
7 N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,  
8 its optical and geometric isomers, salts, and salts of isomers;  
9 (55)  
10 N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
11 (thenylfentanyl), its optical isomers, salts, and salts of isomers;  
12 (56) Thiofentanyl,  
13 N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide, its  
14 optical isomers, salts, and salts of isomers; and  
15 (57) Para-fluorofentanyl,  
16 N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)propanamide,  
17 its optical isomers, salts, and salts of isomers.

18 (b) Any of the following opium derivatives, their salts,  
19 isomers, and salts of isomers, unless specifically excepted,  
20 whenever the existence of such salts, isomers, and salts of  
21 isomers is possible within the specific chemical designation:

- 22 (1) Acetorphine;
- 23 (2) Acetyldihydrocodeine;
- 24 (3) Benzylmorphine;
- 25 (4) Codeine methylbromide;
- 26 (5) Codeine-N-Oxide;
- 27 (6) Cyrenorphine;

- 1 (7) Desomorphine;
  - 2 (8) Dihydromorphine;
  - 3 (9) Drotebanol;
  - 4 (10) Etorphine, except hydrochloride salt;
  - 5 (11) Heroin;
  - 6 (12) Hydromorphenol;
  - 7 (13) Methyldesorphine;
  - 8 (14) Methyldihydromorphine;
  - 9 (15) Morphine methylbromide;
  - 10 (16) Morphine methylsulfonate;
  - 11 (17) Morphine-N-Oxide;
  - 12 (18) Myrophine;
  - 13 (19) Nicocodeine;
  - 14 (20) Nicomorphine;
  - 15 (21) Normorphine;
  - 16 (22) Pholcodine; and
  - 17 (23) Thebacon.
- 18 (c) Any material, compound, mixture, or preparation which  
19 contains any quantity of the following hallucinogenic substances,  
20 their salts, isomers, and salts of isomers, unless specifically  
21 excepted, whenever the existence of such salts, isomers, and salts  
22 of isomers is possible within the specific chemical designation,  
23 and, for purposes of this subdivision only, isomer shall include  
24 the optical, position, and geometric isomers:
- 25 (1) Bufotenine. Trade and other names shall include, but  
26 are not limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;  
27 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;

1 5-hydroxy-N,N-dimethyltryptamine; and mappine;

2 (2) Diethyltryptamine. Trade and other names shall  
3 include, but are not limited to: N,N-Diethyltryptamine; and DET;

4 (3) Dimethyltryptamine. Trade and other names shall  
5 include, but are not limited to: DMT;

6 (4) 4-bromo-2,5-dimethoxyamphetamine. Trade  
7 and other names shall include, but are not limited  
8 to: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; and  
9 4-bromo-2,5-DMA;

10 (5) 4-methoxyamphetamine. Trade and other  
11 names shall include, but are not limited to:  
12 4-methoxy-alpha-methylphenethylamine; and paramethoxyamphetamine,  
13 PMA;

14 (6) 4-methyl-2,5-dimethoxyamphetamine. Trade and  
15 other names shall include, but are not limited to:  
16 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP;

17 (7) 5-methoxy-N,N-dimethyltryptamine;

18 (8) Ibogaine. Trade and other names  
19 shall include, but are not limited to:

20 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido  
21 (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe iboga;

22 (9) Lysergic acid diethylamide;

23 (10) Marijuana;

24 (11) Mescaline;

25 (12) Peyote. Peyote shall mean all parts of the plant  
26 presently classified botanically as *Lophophora williamsii* Lemaire,  
27 whether growing or not, the seeds thereof, any extract from

1 any part of such plant, and every compound, manufacture, salts,  
2 derivative, mixture, or preparation of such plant or its seeds or  
3 extracts;

4 (13) Psilocybin;

5 (14) Psilocyn;

6 (15) Tetrahydrocannabinols, including, but not limited  
7 to, synthetic equivalents of the substances contained in the plant  
8 or in the resinous extractives of cannabis, sp. or synthetic  
9 substances, derivatives, and their isomers with similar chemical  
10 structure and pharmacological activity such as the following: Delta  
11 1 cis or trans tetrahydrocannabinol and their optical isomers,  
12 excluding dronabinol in sesame oil and encapsulated in a soft  
13 gelatin capsule in a drug product approved by the federal Food  
14 and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol  
15 and their optical isomers; and Delta 3,4 cis or trans  
16 tetrahydrocannabinol and its optical isomers. Since nomenclature  
17 of these substances is not internationally standardized, compounds  
18 of these structures shall be included regardless of the numerical  
19 designation of atomic positions covered;

20 (16) 3,4-methylenedioxy amphetamine;

21 (17) 5-methoxy-3,4-methylenedioxy-amphetamine;

22 (18) 3,4,5-trimethoxy amphetamine;

23 (19) N-ethyl-3-piperidyl benzilate;

24 (20) N-methyl-3-piperidyl benzilate;

25 (21) Thiophene analog of phencyclidine. Trade  
26 and other names shall include, but are not limited to:  
27 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of

1 phencyclidine; TPCP; and TCP;  
2 (22) 2,5-dimethoxyamphetamine. Trade and  
3 other names shall include, but are not limited to:  
4 2,5-dimethoxy-alpha-methylphenethylamine; and 2,5-DMA;  
5 (23) Hashish or concentrated cannabis;  
6 (24) Parahexyl. Trade and other  
7 names shall include, but are not limited to:  
8 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo (b,d)pyran;  
9 and Synhexyl;  
10 (25) Ethylamine analog of phencyclidine. Trade  
11 and other names shall include, but are not limited to:  
12 N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;  
13 N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE;  
14 (26) Pyrrolidine analog of phencyclidine. Trade  
15 and other names shall include, but are not limited to:  
16 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP;  
17 (27) 3,4-methylenedioxymethamphetamine (MDMA), its  
18 optical, positional, and geometric isomers, salts, and salts of  
19 isomers;  
20 (28) 4-Bromo-2,5-dimethoxyphenethylamine. Some trade  
21 or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;  
22 alpha-desmethyl DOB; 2C-B; and Nexus;  
23 (29) Alpha-ethyltryptamine. Some trade or other  
24 names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine;  
25 3-(2-aminobutyl) indole; alpha-ET; and AET;  
26 (30) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;  
27 (31) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

1                   (32) Alpha-methyltryptamine, which is also known as AMT;

2                   (33) 5-Methoxy-N,N-diisopropyltryptamine, which is also  
3 known as 5-MeO-DIPT;

4                   (34) Salvia divinorum or Salvinorin A. Salvia divinorum  
5 or Salvinorin A includes all parts of the plant presently  
6 classified botanically as Salvia divinorum, whether growing or not,  
7 the seeds thereof, any extract from any part of such plant, and  
8 every compound, manufacture, derivative, mixture, or preparation of  
9 such plant, its seeds, or its extracts, including salts, isomers,  
10 and salts of isomers whenever the existence of such salts, isomers,  
11 and salts of isomers is possible within the specific chemical  
12 designation; ~~and~~

13                   (35) Any material, compound, mixture, or preparation  
14 containing any quantity of synthetically produced cannabinoids as  
15 listed in subdivisions (i) through (viii) of this subdivision,  
16 including their salts, isomers, and salts of isomers, unless  
17 specifically excepted elsewhere in this section. Since nomenclature  
18 of these synthetically produced cannabinoids is not internationally  
19 standardized and may continually evolve, these structures or  
20 compounds of these structures shall be included under this  
21 subdivision, regardless of their specific numerical designation  
22 of atomic positions covered, so long as it can be determined  
23 through some form of scientific testing or analysis that the  
24 substance contains properties that fit within one or more of the  
25 following categories:

26                   (i) Tetrahydrocannabinols: Meaning tetrahydrocannabinols  
27 naturally contained in a plant of the genus cannabis (cannabis

1 plant), as well as synthetic equivalents of the substances  
2 contained in the plant, or in the resinous extractives of  
3 cannabis, sp. and/or synthetic substances, derivatives, and  
4 their isomers with similar chemical structure and pharmacological  
5 activity such as the following: Delta 1 cis or trans  
6 tetrahydrocannabinol, and their optical isomers Delta 6 cis or  
7 trans tetrahydrocannabinol, and their optical isomers Delta 3,4 cis  
8 or trans tetrahydrocannabinol, and its optical isomers;

9 (ii) Naphthoylindoles: Any compound containing a  
10 3-(1-naphthoyl)indole structure with substitution at the nitrogen  
11 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
12 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
13 whether or not further substituted in the indole ring to any extent  
14 and whether or not substituted in the naphthyl ring to any extent;

15 (iii) Naphthylmethylinindoles: Any compound containing a 1  
16 H-indol-3-yl-(1-naphthyl)methane structure with substitution at the  
17 nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
18 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
19 whether or not further substituted in the indole ring to any extent  
20 and whether or not substituted in the naphthyl ring to any extent;

21 (iv) Naphthoylpyrroles: Any compound containing a  
22 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen  
23 atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl,  
24 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
25 whether or not further substituted in the pyrrole ring to any  
26 extent and whether or not substituted in the naphthyl ring to any  
27 extent;

1           (v) Naphthylideneindenes: Any compound containing  
2 a naphthylideneindene structure with substitution at the  
3 3-position of the indene ring by a alkyl, haloalkyl, alkenyl,  
4 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
5 whether or not further substituted in the indene ring to any extent  
6 and whether or not substituted in the naphthyl ring to any extent;

7           (vi) Phenylacetylindoles: Any compound containing a  
8 3-phenylacetylindole structure with substitution at the nitrogen  
9 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
10 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
11 whether or not further substituted in the indole ring to any extent  
12 and whether or not substituted in the phenyl ring to any extent;

13           (vii) Cyclohexylphenols: Any compound containing a  
14 2-(3-hydroxycyclohexyl)phenol structure with substitution at the  
15 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl,  
16 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
17 whether or not substituted in the cyclohexyl ring to any extent;  
18 and

19           (viii) Benzoylindoles: Any compound containing a  
20 3-(benzoyl)indole structure with substitution at the nitrogen  
21 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
22 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
23 whether or not further substituted in the indole ring to any extent  
24 and whether or not substituted in the phenyl ring to any extent;  
25 and-

26           (36) (A) Any substance containing any quantity of the  
27 following materials, compounds, mixtures, or structures:

1           (i) 3,4-methylenedioxy methcathinone, or bk-MDMA, or  
2 methylone;

3           (ii) 3,4-methylenedioxy pyrovalerone, or MDPV;

4           (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

5           (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or  
6 methedrone;

7           (v) Fluoromethcathinone, or FMC;

8           (vi) Napthylpyrovalerone, or naphyrone; or

9           (vii) Beta-keto-N-methylbenzodioxolylpropylamine; or

10          (B) Unless listed in another schedule, any substance  
11 which contains any quantity of any material, compound, mixture,  
12 or structure, other than bupropion, that is structurally derived  
13 by any means from 2-aminopropan-1-one by substitution at the  
14 1-position with either phenyl, naphthyl, or thiophene ring systems,  
15 whether or not the compound is further modified in any of the  
16 following ways:

17           (i) Substitution in the ring system to any extent  
18 with alkyl, alkoxy, alkylendioxy, haloalkyl, hydroxyl, or halide  
19 substituents, whether or not further substituted in the ring system  
20 by one or more other univalent substituents;

21           (ii) Substitution at the 3-position with an acyclic alkyl  
22 substituent; or

23           (iii) Substitution at the 2-amino nitrogen atom with  
24 alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen  
25 atom in a cyclic structure.

26           (d) Unless specifically excepted or unless listed in  
27 another schedule, any material, compound, mixture, or preparation

1 which contains any quantity of the following substances having  
2 a depressant effect on the central nervous system, including its  
3 salts, isomers, and salts of isomers whenever the existence of  
4 such salts, isomers, and salts of isomers is possible within the  
5 specific chemical designation:

- 6 (1) Mecloqualone;  
7 (2) Methaqualone; and  
8 (3) Gamma-Hydroxybutyric Acid. Some other names include:  
9 GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic  
10 Acid; Sodium Oxybate; and Sodium Oxybutyrate.

11 (e) Unless specifically excepted or unless listed in  
12 another schedule, any material, compound, mixture, or preparation  
13 which contains any quantity of the following substances having  
14 a stimulant effect on the central nervous system, including its  
15 salts, isomers, and salts of isomers:

- 16 (1) Fenethylline;  
17 (2) N-ethylamphetamine;  
18 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;  
19 or 4,5-dihydro-5-phenyl-2-oxazolamine;  
20 (4) Cathinone; 2-amino-1-phenyl-1-propanone;  
21 alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrone;  
22 (5) Methcathinone, its salts, optical isomers,  
23 and salts of optical isomers. Some other names:  
24 2-(methylamino)-propiofenone; alpha-(methylamino)propiofenone;  
25 2-(methylamino)-1-phenylpropan-1-one;  
26 alpha-N-methylaminopropiophenone; methylcathinone;  
27 monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422;

1 AL-463; and UR1432;

2 (6) (+/-) cis-4-methylaminorex; and

3 (+/-) cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine;

4 (7) N,N-dimethylamphetamine;

5 N,N-alpha-trimethyl-benzeneethanamine; and

6 N,N-alpha-trimethylphenethylamine; and

7 (8) Benzylpiperazine, 1-benzylpiperazine.

8 (f) Any controlled substance analogue to the extent

9 intended for human consumption.

10 Schedule II

11 (a) Any of the following substances except those narcotic

12 drugs listed in other schedules whether produced directly or

13 indirectly by extraction from substances of vegetable origin,

14 independently by means of chemical synthesis, or by combination of

15 extraction and chemical synthesis:

16 (1) Opium and opiate, and any salt, compound, derivative,

17 or preparation of opium or opiate, excluding apomorphine,

18 buprenorphine, thebaine-derived butorphanol, dextrorphan,

19 nalbuphine, nalmefene, naloxone, and naltrexone and their

20 salts, but including the following:

21 (i) Raw opium;

22 (ii) Opium extracts;

23 (iii) Opium fluid;

24 (iv) Powdered opium;

25 (v) Granulated opium;

26 (vi) Tincture of opium;

27 (vii) Codeine;

- 1                   (viii) Ethylmorphine;
- 2                   (ix) Etorphine hydrochloride;
- 3                   (x) Hydrocodone;
- 4                   (xi) Hydromorphone;
- 5                   (xii) Metopon;
- 6                   (xiii) Morphine;
- 7                   (xiv) Oxycodone;
- 8                   (xv) Oxymorphone;
- 9                   (xvi) Oripavine;
- 10                  (xvii) Thebaine; and
- 11                  (xviii) Dihydroetorphine;
- 12                  (2) Any salt, compound, derivative, or preparation
- 13 thereof which is chemically equivalent to or identical with any of
- 14 the substances referred to in subdivision (1) of this subdivision,
- 15 except that these substances shall not include the isoquinoline
- 16 alkaloids of opium;
- 17                  (3) Opium poppy and poppy straw;
- 18                  (4) Coca leaves and any salt, compound, derivative, or
- 19 preparation of coca leaves, and any salt, compound, derivative,
- 20 or preparation thereof which is chemically equivalent to or
- 21 identical with any of these substances, including cocaine and
- 22 its salts, optical isomers, and salts of optical isomers, except
- 23 that the substances shall not include decocainized coca leaves or
- 24 extractions which do not contain cocaine or ecgonine; and
- 25                  (5) Concentrate of poppy straw, the crude extract of
- 26 poppy straw in either liquid, solid, or powder form which contains
- 27 the phenanthrene alkaloids of the opium poppy.

1 (b) Unless specifically excepted or unless in another  
2 schedule any of the following opiates, including their isomers,  
3 esters, ethers, salts, and salts of their isomers, esters, and  
4 ethers whenever the existence of such isomers, esters, ethers,  
5 and salts is possible within the specific chemical designation,  
6 dextrorphan excepted:

- 7 (1) Alphaprodine;  
8 (2) Anileridine;  
9 (3) Bezitramide;  
10 (4) Diphenoxylate;  
11 (5) Fentanyl;  
12 (6) Isomethadone;  
13 (7) Levomethorphan;  
14 (8) Levorphanol;  
15 (9) Metazocine;  
16 (10) Methadone;  
17 (11) Methadone-intermediate,  
18 4-cyano-2-dimethylamino-4,4-diphenyl butane;  
19 (12) Moramide-intermediate,  
20 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;  
21 (13) Pethidine or meperidine;  
22 (14) Pethidine-Intermediate-A,  
23 4-cyano-1-methyl-4-phenylpiperidine;  
24 (15) Pethidine-Intermediate-B,  
25 ethyl-4-phenylpiperidine-4-carboxylate;  
26 (16) Pethidine-Intermediate-C,  
27 1-methyl-4-phenylpiperidine-4-carboxylic acid;

- 1 (17) Phenazocine;
- 2 (18) Piminodine;
- 3 (19) Racemethorphan;
- 4 (20) Racemorphan;
- 5 (21) Dihydrocodeine;
- 6 (22) Bulk Propoxyphene in nondosage forms;
- 7 (23) Sufentanil;
- 8 (24) Alfentanil;
- 9 (25) Levo-alpha-acetylmethadol which is also known as
- 10 levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 11 (26) Carfentanil;
- 12 (27) Remifentanil; and
- 13 (28) Tapentadol.

14 (c) Any material, compound, mixture, or preparation  
15 which contains any quantity of the following substances having  
16 a potential for abuse associated with a stimulant effect on the  
17 central nervous system:

- 18 (1) Amphetamine, its salts, optical isomers, and salts of
- 19 its optical isomers;
- 20 (2) Phenmetrazine and its salts;
- 21 (3) Methamphetamine, its salts, isomers, and salts of its
- 22 isomers; and
- 23 (4) Methylphenidate.

24 (d) Any material, compound, mixture, or preparation  
25 which contains any quantity of the following substances having  
26 a potential for abuse associated with a depressant effect on the  
27 central nervous system, including their salts, isomers, and salts

1 of isomers whenever the existence of such salts, isomers, and salts  
2 of isomers is possible within the specific chemical designations:

- 3 (1) Amobarbital;
- 4 (2) Secobarbital;
- 5 (3) Pentobarbital;
- 6 (4) Phencyclidine; and
- 7 (5) Glutethimide.

8 (e) Hallucinogenic substances known as:

- 9 (1) Nabilone. Another name for  
10 nabilone: (+/-)-trans-3-(1,1-dimethylheptyl)-  
11 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one.

12 (f) Unless specifically excepted or unless listed in  
13 another schedule, any material, compound, mixture, or preparation  
14 which contains any quantity of the following substances:

- 15 (1) Immediate precursor to amphetamine and  
16 methamphetamine: Phenylacetone. Trade and other names shall  
17 include, but are not limited to: Phenyl-2-propanone; P2P; benzyl  
18 methyl ketone; and methyl benzyl ketone; or

19 (2) Immediate precursors to phencyclidine, PCP:

- 20 (i) 1-phenylcyclohexylamine; or
- 21 (ii) 1-piperidinocyclohexanecarbonitrile, PCC.

22 Schedule III

23 (a) Any material, compound, mixture, or preparation  
24 which contains any quantity of the following substances having  
25 a potential for abuse associated with a stimulant effect on the  
26 central nervous system, including their salts, isomers, whether  
27 optical, position, or geometric, and salts of such isomers whenever

1 the existence of such salts, isomers, and salts of isomers is  
2 possible within the specific chemical designation:

- 3 (1) Benzphetamine;
- 4 (2) Chlorphentermine;
- 5 (3) Clortermine; and
- 6 (4) Phendimetrazine.

7 (b) Any material, compound, mixture, or preparation  
8 which contains any quantity of the following substances having  
9 a potential for abuse associated with a depressant effect on the  
10 central nervous system:

11 (1) Any substance which contains any quantity of a  
12 derivative of barbituric acid or any salt of a derivative of  
13 barbituric acid, except those substances which are specifically  
14 listed in other schedules of this section;

- 15 (2) Chlorhexadol;
- 16 (3) Lysergic acid;
- 17 (4) Lysergic acid amide;
- 18 (5) Methyprylon;
- 19 (6) Sulfondiethylmethane;
- 20 (7) Sulfonethylmethane;
- 21 (8) Sulfonmethane;
- 22 (9) Nalorphine;

23 (10) Any compound, mixture, or preparation containing  
24 amobarbital, secobarbital, pentobarbital, or any salt thereof and  
25 one or more other active medicinal ingredients which are not listed  
26 in any schedule;

27 (11) Any suppository dosage form containing amobarbital,

1 secobarbital, pentobarbital, or any salt of any of these drugs and  
2 approved by the Food and Drug Administration for marketing only as  
3 a suppository;

4 (12) Any drug product containing gamma-hydroxybutyric  
5 acid, including its salts, isomers, and salts of isomers, for which  
6 an application is approved under section 505 of the Federal Food,  
7 Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on  
8 July 20, 2002;

9 (13) Ketamine, its salts, isomers, and  
10 salts of isomers. Some other names for ketamine:  
11 (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; and

12 (14) Tiletamine and zolazepam or any salt thereof.  
13 Trade or other names for a tiletamine-zolazepam combination  
14 product shall include, but are not limited to: telazol. Trade  
15 or other names for tiletamine shall include, but are not  
16 limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or  
17 other names for zolazepam shall include, but are not limited  
18 to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)  
19 (1,4)-diazepin-7(1H)-one, and flupyrzapon.

20 (c) Unless specifically excepted or unless listed in  
21 another schedule:

22 (1) Any material, compound, mixture, or preparation  
23 containing limited quantities of any of the following narcotic  
24 drugs, or any salts calculated as the free anhydrous base or  
25 alkaloid, in limited quantities as set forth below:

26 (i) Not more than one and eight-tenths grams of codeine  
27 per one hundred milliliters or not more than ninety milligrams per

1 dosage unit, with an equal or greater quantity of an isoquinoline  
2 alkaloid of opium;

3 (ii) Not more than one and eight-tenths grams of codeine  
4 per one hundred milliliters or not more than ninety milligrams per  
5 dosage unit, with one or more active, nonnarcotic ingredients in  
6 recognized therapeutic amounts;

7 (iii) Not more than three hundred milligrams of  
8 dihydrocodeinone which is also known as hydrocodone per one hundred  
9 milliliters or not more than fifteen milligrams per dosage unit,  
10 with a fourfold or greater quantity of an isoquinoline alkaloid of  
11 opium;

12 (iv) Not more than three hundred milligrams of  
13 dihydrocodeinone which is also known as hydrocodone per one hundred  
14 milliliters or not more than fifteen milligrams per dosage unit,  
15 with one or more active, nonnarcotic ingredients in recognized  
16 therapeutic amounts;

17 (v) Not more than one and eight-tenths grams of  
18 dihydrocodeine per one hundred milliliters or not more than ninety  
19 milligrams per dosage unit, with one or more active, nonnarcotic  
20 ingredients in recognized therapeutic amounts;

21 (vi) Not more than three hundred milligrams of  
22 ethylmorphine per one hundred milliliters or not more than fifteen  
23 milligrams per dosage unit, with one or more active, nonnarcotic  
24 ingredients in recognized therapeutic amounts;

25 (vii) Not more than five hundred milligrams of opium per  
26 one hundred milliliters or per one hundred grams, or not more than  
27 twenty-five milligrams per dosage unit, with one or more active,

1 nonnarcotic ingredients in recognized therapeutic amounts; and

2 (viii) Not more than fifty milligrams of morphine per  
3 one hundred milliliters or per one hundred grams with one or more  
4 active, nonnarcotic ingredients in recognized therapeutic amounts;  
5 and

6 (2) Any material, compound, mixture, or preparation  
7 containing any of the following narcotic drug or its salts, as  
8 set forth below:

9 (i) Buprenorphine.

10 (d) Unless contained on the administration's list of  
11 exempt anabolic steroids as the list existed on June 1, 2007,  
12 any anabolic steroid, which shall include any material, compound,  
13 mixture, or preparation containing any quantity of the following  
14 substances, including its salts, isomers, and salts of isomers  
15 whenever the existence of such salts of isomers is possible within  
16 the specific chemical designation:

17 (1) Boldenone;

18 (2) Boldione;

19 (3) Chlorotestosterone (4-chlortestosterone);

20 (4) Clostebol;

21 (5) Dehydrochloromethyltestosterone;

22 (6) Desoxymethyltestosterone;

23 (7) Dihydrotestosterone (4-dihydrotestosterone);

24 (8) Drostanolone;

25 (9) Ethylestrenol;

26 (10) Fluoxymesterone;

27 (11) Formebolone (formebolone);

- 1 (12) Mesterolone;
- 2 (13) Methandienone;
- 3 (14) Methandranone;
- 4 (15) Methandriol;
- 5 (16) Methandrostenolone;
- 6 (17) Methenolone;
- 7 (18) Methyltestosterone;
- 8 (19) Mibolerone;
- 9 (20) Nandrolone;
- 10 (21) Norethandrolone;
- 11 (22) Oxandrolone;
- 12 (23) Oxymesterone;
- 13 (24) Oxymetholone;
- 14 (25) Stanolone;
- 15 (26) Stanozolol;
- 16 (27) Testolactone;
- 17 (28) Testosterone;
- 18 (29) Trenbolone;
- 19 (30) 19-nor-4,9(10)-androstadienedione; and
- 20 (31) Any salt, ester, or ether of a drug or substance
- 21 described or listed in this subdivision if the salt, ester, or
- 22 ether promotes muscle growth.

23 (e) Hallucinogenic substances known as:

- 24 (1) Dronabinol, synthetic, in sesame oil and encapsulated
- 25 in a soft gelatin capsule in a Food and Drug Administration
- 26 approved drug product. Some other names for dronabinol are
- 27 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo

1 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

2 Schedule IV

3 (a) Any material, compound, mixture, or preparation which  
4 contains any quantity of the following substances, including their  
5 salts, isomers, and salts of isomers whenever the existence of  
6 such salts, isomers, and salts of isomers is possible within the  
7 specific chemical designation:

8 (1) Barbital;

9 (2) Chloral betaine;

10 (3) Chloral hydrate;

11 (4) Chlordiazepoxide, but not including librax  
12 (chlordiazepoxide hydrochloride and clindinium bromide) or menrium  
13 (chlordiazepoxide and water soluble esterified estrogens);

14 (5) Clonazepam;

15 (6) Clorazepate;

16 (7) Diazepam;

17 (8) Ethchlorvynol;

18 (9) Ethinamate;

19 (10) Flurazepam;

20 (11) Mebutamate;

21 (12) Meprobamate;

22 (13) Methohexital;

23 (14) Methylphenobarbital;

24 (15) Oxazepam;

25 (16) Paraldehyde;

26 (17) Petrichloral;

27 (18) Phenobarbital;

- 1 (19) Prazepam;
- 2 (20) Alprazolam;
- 3 (21) Bromazepam;
- 4 (22) Camazepam;
- 5 (23) Clobazam;
- 6 (24) Clotiazepam;
- 7 (25) Cloxazolam;
- 8 (26) Delorazepam;
- 9 (27) Estazolam;
- 10 (28) Ethyl loflazepate;
- 11 (29) Fludiazepam;
- 12 (30) Flunitrazepam;
- 13 (31) Halazepam;
- 14 (32) Haloxazolam;
- 15 (33) Ketazolam;
- 16 (34) Loprazolam;
- 17 (35) Lorazepam;
- 18 (36) Lormetazepam;
- 19 (37) Medazepam;
- 20 (38) Nimetazepam;
- 21 (39) Nitrazepam;
- 22 (40) Nordiazepam;
- 23 (41) Oxazolam;
- 24 (42) Pinazepam;
- 25 (43) Temazepam;
- 26 (44) Tetrazepam;
- 27 (45) Triazolam;

- 1 (46) Midazolam;
- 2 (47) Quazepam;
- 3 (48) Zolpidem;
- 4 (49) Dichloralphenazone; and
- 5 (50) Zaleplon.

6 (b) Any material, compound, mixture, or preparation which  
7 contains any quantity of the following substance, including its  
8 salts, isomers, whether optical, position, or geometric, and salts  
9 of such isomers, whenever the existence of such salts, isomers, and  
10 salts of isomers is possible: Fenfluramine.

11 (c) Unless specifically excepted or unless listed in  
12 another schedule, any material, compound, mixture, or preparation  
13 which contains any quantity of the following substances having a  
14 stimulant effect on the central nervous system, including their  
15 salts, isomers, whether optical, position, or geometric, and salts  
16 of such isomers whenever the existence of such salts, isomers,  
17 and salts of isomers is possible within the specific chemical  
18 designation:

- 19 (1) Diethylpropion;
- 20 (2) Phentermine;
- 21 (3) Pemoline, including organometallic complexes and  
22 chelates thereof;
- 23 (4) Mazindol;
- 24 (5) Pipradrol;
- 25 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 26 (7) Cathine. Another name for cathine is  
27 ((+)-norpseudoephedrine);

- 1           (8) Fencamfamin;  
2           (9) Fenproporex;  
3           (10) Mefenorex;  
4           (11) Modafinil; and  
5           (12) Sibutramine.

6           (d) Unless specifically excepted or unless listed in  
7 another schedule, any material, compound, mixture, or preparation  
8 which contains any quantity of the following narcotic drugs, or  
9 their salts or isomers calculated as the free anhydrous base or  
10 alkaloid, in limited quantities as set forth below:

- 11           (1) Propoxyphene in manufactured dosage forms; and  
12           (2) Not more than one milligram of difenoxin and not less  
13 than twenty-five micrograms of atropine sulfate per dosage unit.

14           (e) Unless specifically excepted or unless listed in  
15 another schedule, any material, compound, mixture, or preparation  
16 which contains any quantity of the following substance, including  
17 its salts: Pentazocine.

18           (f) Unless specifically excepted or unless listed in  
19 another schedule, any material, compound, mixture, or preparation  
20 which contains any quantity of the following substance, including  
21 its salts, isomers, and salts of such isomers: Butorphanol.

22           (g) Unless specifically excepted or unless listed in  
23 another schedule, any material, compound, mixture, or preparation  
24 which contains any quantity of the following substance, including  
25 its salts, isomers, and salts of such isomers: Carisoprodol.

26           ~~(g)(1)~~ (h)(1) Unless specifically excepted or unless  
27 listed in another schedule, any material, compound, mixture, or

1 preparation which contains any quantity of the following substance,  
2 including its salts, optical isomers, and salts of such optical  
3 isomers: Ephedrine.

4 (2) The following drug products containing ephedrine, its  
5 salts, optical isomers, and salts of such optical isomers, are  
6 excepted from subdivision ~~(g)(1)~~ (h)(1) of Schedule IV if they  
7 (A) are stored behind a counter, in an area not accessible to  
8 customers, or in a locked case so that a customer needs assistance  
9 from an employee to access the drug product; (B) are sold by a  
10 person, eighteen years of age or older, in the course of his or her  
11 employment to a customer eighteen years of age or older with the  
12 following restrictions: No customer shall be allowed to purchase,  
13 receive, or otherwise acquire more than three and six-tenths grams  
14 of ephedrine base during a twenty-four-hour period; no customer  
15 shall purchase, receive, or otherwise acquire more than nine grams  
16 of ephedrine base during a thirty-day period; and the customer  
17 shall display a valid driver's or operator's license, a Nebraska  
18 state identification card, a military identification card, an alien  
19 registration card, or a passport as proof of identification; (C)  
20 are labeled and marketed in a manner consistent with the pertinent  
21 OTC Tentative Final or Final Monograph; (D) are manufactured and  
22 distributed for legitimate medicinal use in a manner that reduces  
23 or eliminates the likelihood of abuse; and (E) are not marketed,  
24 advertised, or represented in any manner for the indication of  
25 stimulation, mental alertness, euphoria, ecstasy, a buzz or high,  
26 heightened sexual performance, or increased muscle mass:

27 (i) Primatene Tablets; and

1 (ii) Bronkaid Dual Action Caplets, ~~and~~

2 ~~(iii) Paze Hemorrhoidal Ointment.~~

3 Schedule V

4 (a) Any compound, mixture, or preparation containing any  
5 of the following limited quantities of narcotic drugs or salts  
6 calculated as the free anhydrous base or alkaloid, which shall  
7 include one or more nonnarcotic active medicinal ingredients in  
8 sufficient proportion to confer upon the compound, mixture, or  
9 preparation valuable medicinal qualities other than those possessed  
10 by the narcotic drug alone:

11 (1) Not more than two hundred milligrams of codeine per  
12 one hundred milliliters or per one hundred grams;

13 (2) Not more than one hundred milligrams of  
14 dihydrocodeine per one hundred milliliters or per one hundred  
15 grams;

16 (3) Not more than one hundred milligrams of ethylmorphine  
17 per one hundred milliliters or per one hundred grams;

18 (4) Not more than two and five-tenths milligrams of  
19 diphenoxylate and not less than twenty-five micrograms of atropine  
20 sulfate per dosage unit;

21 (5) Not more than one hundred milligrams of opium per one  
22 hundred milliliters or per one hundred grams; and

23 (6) Not more than five-tenths milligram of difenoxin and  
24 not less than twenty-five micrograms of atropine sulfate per dosage  
25 unit.

26 (b) Unless specifically exempted or excluded or unless  
27 listed in another schedule, any material, compound, mixture, or

1 preparation which contains any quantity of the following substances  
2 having a stimulant effect on the central nervous system, including  
3 its salts, isomers, and salts of isomers: Pyrovalerone.

4 (c) Unless specifically exempted or excluded or unless  
5 listed in another schedule, any material, compound, mixture, or  
6 preparation which contains any quantity of the following substances  
7 having a depressant effect on the central nervous system, including  
8 its salts, isomers, and salts of isomers:

9 (1) Ezogabine  
10 [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic  
11 acid ethyl ester];

12 (2) Lacosamide  
13 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]; and

14 (3) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
15 acid].

16 Sec. 5. Since an emergency exists, this act takes effect  
17 when passed and approved according to law.

18 2. Renumber the remaining sections and correct the  
19 repealer section accordingly.